metabolic dysfunction-associated steatohepatitis

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY 09/20/2025

This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Clinical Updates news

Ervogastat Alone and Combined with Clesacostat for Metabolic Dysfunction-Associated Steatohepatitis with Advanced Fibrosis: Insights from the MIRNA Phase 2 Trial

By MedXY 09/17/2025

The MIRNA study evaluated ervogastat, alone and with clesacostat, in patients with biopsy-confirmed MASH and F2-F3 fibrosis, showing combination therapy achieved significant efficacy in resolving MASH without fibrosis worsening and a manageable safety profile.

Diabetes & Endocrinology Gastroenterology Specialties

Efruxifermin Demonstrates Promising 96-Week Efficacy and Safety in Treating Metabolic Dysfunction-Associated Steatohepatitis: Insights from the Phase 2b HARMONY Trial

By MedXY 08/27/2025

The HARMONY trial reveals that once-weekly efruxifermin significantly improves liver fibrosis without worsening MASH over 96 weeks, with a favorable safety profile supporting its phase 3 evaluation.

Clinical Updates Diabetes & Endocrinology Gastroenterology news Specialties

HTD1801 Shows Promising Histologic Improvement in Metabolic Dysfunction-Associated Steatohepatitis: Insights from Preclinical and Phase 2 Clinical Studies

By MedXY 08/24/2025

HTD1801 (berberine ursodeoxycholate) significantly improves liver histology and reduces fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) as demonstrated by preclinical models and a Phase 2 trial.